Tarsus Pharmaceuticals (TARS) Cash from Operations Growth (1y) (2020 - 2026)
Tarsus Pharmaceuticals (TARS) Cash from Operations Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.97 Bn | 466.18 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.05 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.42 Bn | 959.66 Mn | 158.60% |
| 10 | Tarsus Pharmaceuticals | 2.62 Bn | 2.52 Bn | 152.66 Mn | -19.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.37% |
| Dec 31, 2025 | 187.14% |
| Sep 30, 2025 | 311.01% |
| Jun 30, 2025 | -104.02% |
| Mar 31, 2025 | 45.35% |
| Dec 31, 2024 | 43.61% |
| Sep 30, 2024 | 73.26% |
| Jun 30, 2024 | 39.55% |
| Mar 31, 2024 | -72.00% |
| Dec 31, 2023 | -261.73% |
| Sep 30, 2023 | -73.89% |
| Jun 30, 2023 | -459.43% |
| Mar 31, 2023 | -43.73% |
| Dec 31, 2022 | 10.29% |
| Sep 30, 2022 | -361.68% |
| Jun 30, 2022 | -120.72% |
| Mar 31, 2022 | -29.61% |
| Dec 31, 2021 | -21.05% |
| Sep 30, 2021 | 208.22% |
| Jun 30, 2021 | 903.72% |